Malaysia Oral Anti-Diabetic Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 274 Million |
| Market Size (2028) | USD 333 Million |
| CAGR (2024 - 2029) | 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Malaysia Oral Anti-Diabetic Drug Market Analysis
The Malaysia Oral Anti-Diabetic Drug Market size is estimated at USD 274 million in 2024, and is expected to reach USD 333 million by 2028, growing at a CAGR of greater than 3% during the forecast period (2024-2028).
According to the Health Ministry, one in five Malaysians, or around 3.9 million adults and older, have diabetes. There are more young people with diabetes. The prevalence of diabetes is rising among younger people, with the number of diabetics in this age group more than doubling in the past 15 years.
Diabetes complications, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, are becoming more prevalent due to the expanding diabetes population. Most coronavirus mortality in Malaysia is caused by underlying comorbidities, with diabetes and hypertension at the top.
Diabetes among young people is on the rise. With the number of patients between the ages of 18 and 40 having doubled over the previous 15 years, younger individuals are developing diabetes. The burden of diabetes and its consequences, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, is increasing as the number of people with diabetes grows.
Malaysia Oral Anti-Diabetic Drug Market Trends
Sulfonylurea Segment Occupied the Highest Market Share in the Malaysia Oral Anti-Diabetic Drugs Market in the current year.
Regarding revenue, the sulfonylurea segment is anticipated to lead the Malaysia Oral Anti-Diabetic Drugs Market and post a CAGR of over 1% during the forecast year.
Medications of the sulfonylurea family are used to treat type 2 diabetes mellitus. The indications, mode of action, administration, side effects, contraindications, monitoring, and toxicity of sulfonylureas are described in this activity. It will also be emphasized how crucial it is to manage sulfonylurea-using patients using a multidisciplinary approach.
The earliest type of oral diabetes treatment, sulfonylureas, dates back to the 1950s. The phenyl-sulfonyl-urea structure seen in all sulfonylureas produces the hypoglycemia effect. Sulfonylureas are used as monotherapy or in conjunction with other oral or injectable treatments by patients with type 2 diabetes mellitus.
With an annual cost of almost 600 million US dollars, Malaysia has one of the highest rates of diabetes globally and the highest rate in the Western Pacific region. Several factors, such as population growth, population aging, urbanization, and rising obesity and physical inactivity rates, influence the expanding tendency. This study was undertaken to thoroughly identify, define, and quantify Malaysia's pooled prevalence of diabetes and prediabetes in light of the rising prevalence of diabetes and its impacts.
The most effective hypoglycaemic drug for treating diabetes is insulin therapy; however, if insulin is kept improperly, its effectiveness will degrade. Diabetes and other NCDs are responsible for more than 70% of all fatalities in Malaysia. Obesity causes more than seven-fold.
AstraZeneca and the Malaysian Endocrine & Metabolic Society (MEMS) support a community project. With the assistance of various pharmacies and media partners, the first survey was conducted online. This initial survey aims to benchmark Malaysia's awareness level and pinpoint significant knowledge gaps. The 2,539 replies from this year (which have been stratified to reflect the whole population) provided valuable data that will influence how AstraZeneca and MEMS conceptualize public education programs in the coming years.
The increasing Diabetes Population in Malaysia is driving the market.
The Malaysian government has implemented diabetes prevention and control programs nationwide since the prevalence of diabetes and prediabetes is rising. To lower the prevalence of diabetes in the country, the Malaysian government should develop a comprehensive strategy and plan to enhance diabetes awareness, management, prevention, and treatment. Key contributors to the younger diabetes population in Malaysia are being overweight and obese. In Malaysia, one in two adults is overweight or obese, according to a recent NHMS.
High blood glucose or sugar levels are a sign of diabetes. It is a condition brought on by the body's inability to produce enough of the hormone insulin to regulate the level of blood sugar. It may also result from insulin resistance, which is the ineffective utilization of insulin by the body. Obesity, unhealthful eating patterns, sedentary lifestyles, and heredity influence this process. According to the National Diabetes Registry (NDR) of the ministry, 84% of diabetic patients in Malaysia who are between the ages of 18 and 40 are overweight.
The Sama-Sama program, which seeks to empower family members and carers to offer support for persons living with diabetes to enhance control and outcomes of the condition, is a project that the ministry is actively investigating. To train healthcare professionals and, subsequently, carers, the church is collaborating with the commercial sector as part of the program. The Sama-Sama program, which seeks to empower family members and carers to support people living with diabetes to improve disease control and outcomes, is now being looked into by the ministry. The government is working on a program to teach medical professionals who would then train caretakers in conjunction with the private sector.
It is therefore anticipated to drive the category expansion during the forecast period because of the factors above.
Malaysia Oral Anti-Diabetic Drug Industry Overview
The Malaysia oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Malaysia Oral Anti-Diabetic Drug Market Leaders
-
Astrazeneca
-
Astellas
-
Janssen
-
Eli Lilly
-
Sanofi
*Disclaimer: Major Players sorted in no particular order
Malaysia Oral Anti-Diabetic Drug Market News
- June 2023: The FDA has approved the drugs Jardiance and Synjardy to be taken by children ages 10 and older who have type 2 diabetes.
- May 2022: Tirzepatide (Mounjaro) was approved for treating Type 2 diabetes in adults. Tirzepatide's FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist.
Malaysia Oral Anti-Diabetic Drug Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMalaysia Oral Anti-Diabetic Drug Industry Segmentation
Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in Type 2 diabetes care. The Malaysia Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
Malaysia Oral Anti-Diabetic Drug Market Research Faqs
How big is the Malaysia Oral Anti-Diabetic Drug Market?
The Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million in 2024 and grow at a CAGR of greater than 3% to reach USD 333 million by 2028.
What is the current Malaysia Oral Anti-Diabetic Drug Market size?
In 2024, the Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million.
Who are the key players in Malaysia Oral Anti-Diabetic Drug Market?
Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Malaysia Oral Anti-Diabetic Drug Market.
What years does this Malaysia Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?
In 2023, the Malaysia Oral Anti-Diabetic Drug Market size was estimated at USD 265.78 million. The report covers the Malaysia Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Malaysia Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Malaysia Oral Anti-Diabetic Drug Industry Report
Statistics for the 2024 Malaysia Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Malaysia Oral Anti-Diabetic Drug analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
